Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
Covered in this story
What has happened since
- Sanofi is up 0.7% since this was published, 19 days ago.
- Regeneron Pharmaceuticals is up 7.9% since this was published, 19 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SAN.PA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Sanofi →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.